Efficacy of Non-invasive Neuromodulation Treatments for COVID-19 Sequelae
NCT ID: NCT06544395
Last Updated: 2025-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
104 participants
INTERVENTIONAL
2026-01-01
2026-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- Is non-invasive neuromodulation effective as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19.
Researchers will compare non-invasive neuromodulation to a placebo (treatment with the machine turned off).
Participants will:
* Be evaluated before starting treatment.
* Be evaluated 3 weeks after.
* Be evaluated at 5 weeks, or 15 sessions or completion of treatment.
* Be evaluated 6 weeks after finishing the treatment or 11 weeks after starting treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Modulated Auditory Stimulation on Interaural Auditory Perception
NCT05441891
Study of Music and Speech Perception in New Cochlear Implanted Subjects Using or Not a Tonotopy Based Fitting
NCT04922619
Evaluation of the Effect of a Visio-Hearing Training Protocol on Spatial Hearing in Subjects With Hearing Loss
NCT04183348
Collection of Clinical Data and Specimens for Research in Hearing, Balance, Taste, Smell, Voice, Speech, and Language Disorders.
NCT05670496
Pupillometry Techniques Usage to Quantify the Programming Parameters Effect in the Auditory Effort in Zti Opticon Cochlear Implant Adult Users
NCT05300230
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Likewise, non-invasive neuromodulation acts with a pump of ions, generating endogenous stimuli that modulate the central nervous system.
The aim of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19.
To carry out this study, pain was measured with the visual analogue scale. It was also measured the joint amplitude, a muscle assessment with the help of a strength dynamometer, the patient's independence with the Katz index and the functionality of the lower or upper limbs, depending on the affected joint.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients receiving non invasive neuromodulation treatment.
Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; who will receive non invasive neuromodulation treatment.
Non invasive neuromodulation therapy
In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.
Each intervention lasted 60 minutes. The intensity will be programmed in all sessions at Low, following the Arndt-Schulz law. The treatment was distributed in 3 phases: phase 1 of preparation, phase 2 to reduce fatigue and phase 3 to enhance autonomic improvement.
Patients receiving traditional treatment.
Patients receiving only traditional therapy. Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; who will receive treatment of traditional therapy.
Manual therapy
Common manual therapy administered for said pathology by traditional physiotherapy and therapeutic exercise.
Patients receiving placebo treatment.
Patients receiving placebo. Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; to those who will be administered placebo (device off, without emitting).
Placebo with non invasive neuromodulation
In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.
Each intervention lasted 60 minutes. The treatment was carried out with the machine turned off.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non invasive neuromodulation therapy
In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.
Each intervention lasted 60 minutes. The intensity will be programmed in all sessions at Low, following the Arndt-Schulz law. The treatment was distributed in 3 phases: phase 1 of preparation, phase 2 to reduce fatigue and phase 3 to enhance autonomic improvement.
Manual therapy
Common manual therapy administered for said pathology by traditional physiotherapy and therapeutic exercise.
Placebo with non invasive neuromodulation
In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.
Each intervention lasted 60 minutes. The treatment was carried out with the machine turned off.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a positive diagnosis of COVID-19.
* Patients with post-COVID-19 sequelae with musculoskeletal, respiratory or neurological symptoms due to taste or smell lasting at least 30 days, with no history of respiratory and/or neurological and/or musculoskeletal diseases.
* Patients who signed the informed consent.
Exclusion Criteria
* Healthy people with no history of neurological, neurological and/or respiratory and/or musculoskeletal diseases
* Patients with secondary diseases that could directly affect the systems to be evaluated who were not diagnosed positive for COVID-19.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinica Gema Leon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
GEMA LEÓN BRAVO
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GEMA LEÓN BRAVO
Role: PRINCIPAL_INVESTIGATOR
Departamento de Enfermería, Farmacología y Fisioterapia de la Universidad de Córdoba
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gema León Physiotherapy and Rehabilitation Clinic
Córdoba, Andalusia, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NO INVASIVE NEUROM-COVID-19
Identifier Type: OTHER
Identifier Source: secondary_id
NO INVASIV NEUROMOD COVID-19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.